Porownanie ekspresji receptorow estrogenowych i progesteronowych w gruczolakorakach gruczolu sutkowego u suk z aktywnoscia mitotyczna komorek nowotworowych

• Autorzy: Nowak M , Madej J.A. , Dziegiel P.

Warianty tytułu

EN

Comparison of expressions of oestrogen and progesterone receptors in adenocarcinomas of the mammary gland in bitches with mitotic activity of neoplastic cells

• Języki publikacji: PL

Abstrakty

EN

The study aimed at monitoring the expression of oestrogen (ER) and progesterone (PGR) receptors in mammary gland adenocarcinomas in bitches as compared to the mitotic activity of the neoplastic cells. Material for the study involved samples of mammary tumors obtained during surgery from 48 bitches of various races, aged 7 to 15 years. The obtained preparations were microphotographed and the patterns were subjected to computer-assisted image analysis in a system consisting of a computer linked to an Axiophot light microscope (Carl Zeiss). The expression of ER, PgR and of Ki-67 was evaluated using a semi-quantitative scale which involved evaluating the proportion of positive cells (0-5% no reaction [], 6-25%: weak reaction [+], 26-50%: moderate reaction [++], above 50%: intense reaction [+++]). The evident deficit of ER observed in our studies might indicate an oestrogen independency of the adenocarcinomas in bitches. This, however, does not preclude involvement of the receptors at earlier stages of carcinogenesis. The obtained strong correlation between expressions of Ki-67 and that of PgR (r=0.67), in view of the high prognostic value of Ki-67 expression, confirmed in numerous studies, allow the conclusion that presence of progesterone receptors in the cells of mammary gland adenocarcinoma in bitches is linked to the augmented proliferative potential of the tumors, similarly as it has been demonstrated in mammary glands in females.

Słowa kluczowe

PL

nasilenie ekspresji; bialko Ki-67; receptory estrogenowe; nowotwory; stopien agresywnosci guza; receptory progesteronowe; psy; suki; ekspresja receptorow; gruczolakorak gruczolu sutkowego

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 10
• Strony: 1211-1215
• Opis fizyczny: s.1211-1215,rys.,fot.,bibliogr.

Twórcy

autor

Nowak M

• Uniwersytet Przyrodniczy we Wroclawiu, ul.Norwida 31, 50-375 Wroclaw

autor

Madej J.A.

autor

Dziegiel P.

Bibliografia

• 1.Amundadfottir L. T., Leder P.: Signal transduction pathways activated and reguired for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998, 16, 737-746.
• 2.Andersen J., Thorpe S. M., King W., Rose C., Christensen I., Rasmussen B. B., Poulsen H. S.: The prognosic value of immunohistochemical estrogen receptor analysis in paraffin embedded and frozen sections versus that of steroid- -binding assays. Eur. J. Cancer 1990, 26, 442-449.
• 3.Barnard N. J., Hall P. A., Lemoine N. R., Kadarr N.: Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J. Pathol. 1987, 152, 287-295.
• 4.Bates N. P., Hurst H. C.: An intron 1 enhancer element mediates oestrogen- -induced suppression of ERBB2 expression. Oncogene 1997, 15, 473-481.
• 5.Brown D. C., Gatter K. C.: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990, 17, 489-503.
• 6.Brünner N., Boulay V., Fojo A., Freter C. E., Lippman M. E., Clarke R.: Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 1993, 53, 283-290.
• 7.Bunone G., Briand P. A., Miksicek R. J., Pcard D.: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosporylation. EMBO J. 1996, 15, 2174-2183.
• 8.Burcombe R. J., Makris A., Richman P. I., Daley F. M., Noble S., Pittam M., Wright D., Allen S. A., Dove J., Wilson G. D.: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 2005, 92, 147-155.
• 9.Giziñski S., Boryczko Z., Katkiewicz M., Bostedt H.: Białko Ki-67 jako wskażnik prognostyczny w nowotworach gruczołu mlekowego u suk. Medycyna Wet. 2003, 59, 888-891.
• 10.Goldhirsch A., Wood W. C., Senn H. J., Glick J. H., Gelber R. D.: IX International consensus conference on primary treatment of breast cancer. Cancer Res. 1996, 140, 325-335.
• 11.Howell A., DeFriend D., Robertson J., Blamey R., Walton P.: Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, 345, 29-30.
• 12.Jeng M. H., Shupnik M. A., Bender T. P., Westin E. H., Bandyopadhyay D., Kumar R., Masamura S., Santen R. J.: Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998, 139, 4164-4174.
• 13.Keen J. C., Davidson N. E.: The biology of breast carcinoma. Cancer suppl. 2003, 97, 825-833.
• 14.Kordek R., Kusiñska R., P³uciennik E., Bednarek A.: Nowe molekularne czynniki prognostyczne u chorych na raka piersi. Wspó³cz. Onkol. 2004, 8, 296-302.
• 15.Kozłowski W., Szacikowska E.: Współczesna interpretacja niepowodzeñ hormonoterapii raka piersi. Współcz. Onkol. 2001, 5, 99-104.
• 16.Levenson A. S., Jordan V. C.: MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997, 57, 3071-3078.
• 17.Lewis T. S., Shapiro P. S., Ahn N. G.: Signal transduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74, 139-149.
• 18.Martan de Las Mulas J., Millan Y., Dios R.: A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet. Pathol. 2005, 42, 200-212.
• 19.Martin P. M., Cotard M., Mialot J. P., Andrà F., Raynaud J. P.: Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother. Pharmacol. 1984, 12, 13-17.
• 20.Millanta F., Calandrella M., Bari G., Niccolini M., Vannozzi I.: A Poli Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res. Vet. Sci. 2005, 79, 225-232.
• 21.Parczyk K., Schneider M. R.: The future of antihormone therapy: innovations based on an established principle. J. Cancer Res. Clin. Oncol. 1996, 122, 383-396.
• 22.Pena L., Perez-Alenza M. D., Rodriguez-Bertos A., Nieto A.: Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res. Treat. 2003, 78, 141-148.
• 23.Pinkas-Kramarski R., Shelly M., Glathe S., Ratzkin B. J., Yarden Y.: Neu differentiation factor/neuregylin isforms activitate receptor combination. J. Biol. Chem. 1996, 271, 1929-1932.
• 24.Ravdin P. M., Green S., Mehn K.: Prognostic significance of progesteron receptor levels in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen a results of prospective Southwest Oncology Group Study. J. Clin. Oncol. 1992, 10, 1284-1291.
• 25.Sartin E. A., Barnes S., Kwapien R. P., Wolfe L. G.: Estrogen and progesterone receptor status of mammary carcinomas and correlation with clinical outcome in dogs. Am. J. Vet. Res. 1992, 53, 2196-2200.
• 26.Sobczak-Filipiak M., Malicka E.: Estrogen receptors in canine mammary gland tumours. Pol. J. Vet .Sci. 2002, 5, 1-5.
• 27.Szacikowska E., Kozłowski W.: Receptory HER/ErbB w prawidłowym nabłonku i w kancerogenezie. Współcz. Onkol. 2000, 1, 7-12.